CH BIOTECH SER (08037) announced a major milestone for its flagship project, Pengbo (Hainan) Boron Neutron Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China. On November 20, 2025, the hospital's NeuCure® neutron irradiation system—the core equipment for boron neutron capture therapy (BNCT)—successfully achieved its first beam extraction, officially entering the final clinical commissioning phase. This marks a critical milestone in the project's advancement and lays a solid foundation for the hospital's future operations.

Leveraging the supportive policies of the Boao Lecheng Pilot Zone, the NeuCure® system is currently the only BNCT system globally to have obtained formal medical device registration approval and can be directly applied in routine clinical treatment (outside clinical trial phases). Clinical treatment services are expected to commence in Q1 2026.

The successful beam extraction confirms that all core system parameters meet design specifications, signifying the transition from equipment installation to beamline commissioning. This achievement establishes a strong foundation for subsequent critical tasks, including precise neutron flux regulation, beam physics validation, and biological effect assessment. It also ensures the device can proceed as planned to deliver safe and precise BNCT services for cancer patients.